Exclusive Summary

• Manufactured in a US-FDA GMP certified facility, guaranteeing top-tier global quality and enabling distributors to achieve expedited, audit-free registrations in multiple target countries.
• Being the first-in-class PARP inhibitor listed on the WHO Essential Medicines List, it targets huge global patient populations across ovarian, breast, and prostate cancers.
• Offers highly lucrative margins for distributors by leveraging a substantial cost advantage over the extremely expensive originator (often >$10,000/month).
• The optimized 100mg/150mg tablet formulations dramatically reduce pill burden, positioning distributors to swiftly capture market share as core patents expire globally.